Strong fit with strategy to serve high-growth sustainable end markets of agritech and industrial water treatment Enhances digital connectivity to Dosatron® smart dosing pump system in Precision and Science Technologies Segment (PST) to improve dosing
- Phase III-enabling activities for otenaproxesul proceeding well; AME study begins next week - Ended year with a strong $72 million cash position, providing over two years of runway and fully funding Phase III adaptive trial TORONTO--(BUSINESS WIRE)--A
LAS VEGAS & TORONTO--(BUSINESS WIRE)--Flower One Holdings Inc. ("Flower One" or the "Company") (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today provides its fifth bi-weekly status report further to the C
TORONTO--(BUSINESS WIRE)--Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”) today announced that it has elected to withdraw its previously announced public offering of common shares (the “Offering”). In light of mar
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will participate in a v
- Enables rapid advancement of multiple drug discovery programs to exploit hydrogen sulfide platform in new disease areas TORONTO--(BUSINESS WIRE)--#collaboration--Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the Company) announced today that the Company’s licensing partner, Otsuka Pharmaceutical Europe Ltd. (OPEL), filed an initial Marketing
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the addition of Dr. Thomas Laughren, to the Clinical Advisory Board.
As the province re-opens and new variants emerge in Canada, testing for infectiousness is more important than ever WATERLOO, Ontario--(BUSINESS WIRE)--#COVID19Ontario--Haven Testing is pleased to announce the availability of BTNX Rapid Response COVID-19
Game Changers is the first report to compile Canada’s extensive activity in alternative protein development in one place.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.